A

Committee Member Biographies

Guy H. Palmer, D.V.M., Ph.D. (Chair), holds the Jan and Jack Creighton Endowed Chair at Washington State University (WSU) where he is the Regents Professor of Pathology and Infectious Diseases, Senior Director of Global Health, and Chief Scientist for the COVID-19 Taskforce. He also serves as Chair of WSU Global Health–Kenya. Dr. Palmer was elected to the National Academy of Medicine (NAM) in 2006, is a Medical Sciences Fellow of the American Association for the Advancement of Science, and is a founding member of the Washington State Academy of Sciences, where he served as the President from 2012 to 2013. Dr. Palmer serves the National Academies as a member of the Board on Global Health and on the membership committee of the NAM. He serves on the Executive Roundtable of the Washington Global Health Alliance and chairs the Pacific Northwest Antibiotic Resistance Coalition. Dr. Palmer earned a B.S. (biology, summa cum laude) and a D.V.M., both from Kansas State University, and received his Ph.D. in infectious diseases from WSU. He completed his residency in pathology and laboratory medicine and is board certified in pathology. He holds honorary doctorates from the University of Bern (Switzerland), where he completed his fellowship in the Institute of Pathology, and from Kansas State University, where he serves on the External Advisory Board for the Biosecurity Institute. He has been recognized with the Poppensiek Professorship at Cornell University, the IBM Professorship at Colby College, the Schalm Lecturership at the University of California, the Distinguished Scientist Lectureship at

the National Institutes of Health, the Science in Medicine Lectureship at the University of Washington, and the Merck Award for Creativity.

Michael Baym, Ph.D., is an Assistant Professor of biomedical informatics at Harvard University. His research is centered around the problem of antibiotic resistance at the intersection of experimental, theoretical, and computational techniques. His work ranges from understanding the basic mechanisms of evolution to the development of algorithms for computation on massive biological datasets. Dr. Baym received his Ph.D. in mathematics from the Massachusetts Institute of Technology and was a postdoctoral fellow at Harvard Medical School in systems biology. He has won several awards, including a Packard Fellowship, a Pew Biomedical Scholarship, and a Sloan Research Fellowship. He is also a part-time inventor, holding more than four dozen issued U.S. patents.

César de la Fuente-Nunez, Ph.D., is a Presidential Assistant Professor at the University of Pennsylvania, where he leads the Machine Biology Group, whose goal is to combine the power of machines and biology to understand, prevent, and treat infectious diseases. Current application areas in his lab include developing novel approaches for antibiotic discovery, building tools for microbiome engineering, and creating low-cost diagnostics. Specifically, he pioneered the development of the first antibiotic designed by a computer with efficacy in animal models, designed pattern recognition algorithms for antibiotic discovery, successfully reprogrammed venoms into novel antimicrobials, created novel resistance-proof antimicrobial materials, and invented rapid low-cost diagnostics for COVID-19 and other infectious diseases. Dr. de la Fuente-Nunez is a National Institutes of Health Maximizing Investigators’ Research Award investigator and a Brain & Behavior Research Foundation Young Investigator and has received recognition and research funding from numerous other groups. Dr. de la Fuente-Nunez was recognized by MIT Technology Review in 2019 as one of the world’s top innovators for “digitizing evolution to make better antibiotics.” He was selected as the inaugural recipient of the Langer Prize (2019), an American Chemical Society (ACS) Kavli Emerging Leader in Chemistry (2020), and received the Nemirovsky Prize (2020), the American Institute of Chemical Engineers’ 35 Under 35 Award (2020) and the ACS Infectious Diseases Young Investigator Award (2020). In addition, he was named a Boston Latino 30 Under 30, a 2018 Wunderkind by STAT News, a Top 10 Under 40 of 2019 by GEN, a Top 10 MIT Technology Review Innovator Under 35 (Spain), 30 Rising Leaders in the Life Sciences, and he received the 2019 Society of Hispanic Professional Engineers Young Investigator Award in addition to the Young Innovator in Cellular and Molecular Bioengineering and the Biomedical

Engineering Society Cellular and Molecular Bioengineering Rising Star Award, both in 2021. Also in 2021, he received the Thermo Fisher Award and the Engineering Medicine and Biology Society Academic Early Career Achievement Award “for the pioneering development of novel antibiotics designed using principles from computation, engineering, and biology.” Most recently, Dr. de la Fuente-Nunez was awarded the prestigious Princess of Girona Prize for Scientific Research. His scientific discoveries have yielded around 100 peer-reviewed publications, including papers in Nature Communications, Proceedings of the National Academy of Sciences of the United States of America, ACS Nano, Cell, Nature Biomedical Engineering, Nature Chemical Biology, Nature Communications Biology, Advanced Materials, and multiple patents.

Jennifer Dien Bard, Ph.D., D(ABMM), F(CCM), is an Associate Professor of pathology with Clinical Scholar designation in the Department of Pathology in the Keck School of Medicine at the University of Southern California. She is the Director of the Clinical Microbiology and Virology Laboratories at Children’s Hospital Los Angeles (CHLA) and the Chief of Academic and Research Development in the Department of Pathology and Laboratory Medicine at CHLA. Dr. Dien Bard is also the Program Director of the Medical and Public Health Microbiology postdoctoral fellowship program at CHLA. She is a Diplomate of the American Board of Medical Microbiology. Dr. Dien Bard serves on several committees and working groups for organizations, including the Association for Molecular Pathology, the American Society for Microbiology (ASM), the Clinical and Laboratory Standards Institute (CLSI), and the Antimicrobial Resistance Leadership Group (ARLG). She is currently a member of the CLSI Methods and Development Standardization working group and the Co-Chair of the Coagulase-negative Staphylococcus species ad hoc working group. She also serves as a member of the ARLG Pediatric working group and the ARLG Diagnostics committee. She is a voting member for a number of CLSI documents, including Principles and Procedures for Blood Culture and Methods for active surveillance of multidrug-resistant organisms, and she has served on the ASM Laboratory Medicine Best Practice Guidelines Committee for the diagnosis of Clostridioides difficile infection and Bloodstream infections. Dr. Dien Bard also served on the editorial board of the Journal of Clinical Microbiology and the Journal of Clinical Virology, and she is an Editor for Microbiology Spectrum Journal. Prior to joining this committee, Dr. Dien Bard consulted with BioFire Diagnostics, Accelerate Diagnostics, and Karius, Inc. She is also a site Principal Investigator at CHLA for trials sponsored by Luminex Corporation, BioFire Diagnostics, and ChromaCode. Dr. Dien Bard has published more than 90 scientific papers and is a frequent speaker in the areas of

rapid molecular diagnostics for the identification of infectious diseases pathogens and detection of genotypic and phenotypic antimicrobial resistance. Her clinical research studies explore the application and effects of laboratory diagnostic, particularly molecular diagnostics, on patient diagnosis, antimicrobial utilization, and overall clinical outcome. Dr. Dien Bard received her B.Sc. in medical laboratory sciences and her Ph.D. in medical sciences from the University of Alberta, Canada. She completed a postdoctoral fellowship in medical and public health microbiology at the University of California, Los Angeles.

Marta Gomez-Chiarri, Ph.D., is an aquatic pathologist and a Professor at The University of Rhode Island (URI), where she has been since 1997. Dr. Gomez-Chiarri earned her Ph.D. in biochemistry and molecular biology from the Universidad Complutense de Madrid (Spain) in 1992. Prior to joining URI, she was a postdoctoral fellow at Hopkins Marine Station, Stanford University, where she worked with biotechnological approaches to the culture of several aquatic species, including trout and abalone. Dr. Gomez-Chiarri held the position of the Chair of the Department of Fisheries, Animal, and Veterinary Sciences (2014–2020) and is currently the Graduate Coordinator for programs in the areas of aquaculture and fisheries and sustainable agriculture and food systems. She is also coordinator of the interdisciplinary Sustainable Agriculture and Food Systems undergraduate program, a major that explores the food chain, from farm to plate to waste and back, emphasizing sustainability, impacts on human health, and resilience from economic, environmental, and societal viewpoints. Her research interests include the use of multidisciplinary approaches to the prevention and management of diseases in marine organisms, from probiotics and microbial–microbial interactions to genomics and comparative immunology. Her collaborative national and international research on marine diseases is driven by a desire to ensure equitable access to healthy food that is sustainably produced.

Guillaume Lhermie, D.V.M., M.Sc., Ph.D., is an Associate Professor in animal health and veterinary public health economics at the University of Toulouse, France, and an Adjunct Assistant Professor at Cornell University in Ithaca, New York. A veterinarian by training, he also has an M.Sc. in economics and a Ph.D. in pharmaco-epidemiology and innovation. Before working in academia, Dr. Lhermie worked in veterinary private practice for a few years and in the pharmaceutical industry as a Research and Development Project Manager and a Medical Director for more than 8 years. Dr. Lhermie’s research interests are in One Health and infectious diseases challenges, specifically the interface of animal agriculture and human health. He is studying the economics of antimicrobial use and

resistance at the farm, supply chains, and global levels. Most recently, his research emphasis has been focusing on sustainability challenge, where he develops qualitative and quantitative models aiming to analyze the effect of antimicrobial use on social-ecological systems, to inform policy makers. Dr. Lhermie also serves as an expert in animal health economics for governmental organizations and nongovernmental organizations.

Preeti Malani, M.D., M.S.J., is the University of Michigan’s Chief Health Officer and a Professor of medicine in the Division of Infectious Diseases. She is also the Director of the University of Michigan’s National Poll on Healthy Aging. Her clinical expertise includes both infectious diseases and geriatric medicine. Dr. Malani is a graduate of the University of Michigan. She received her M.D. from the Wayne State University School of Medicine. Prior to medical school, she completed a Master’s in Journalism at Northwestern University’s Medill School of Journalism. She completed her internal medicine residency and infectious diseases fellowship at the University of Michigan where she also received a master’s degree in clinical research design and statistical analysis. Dr. Malani completed fellowship training in geriatric medicine at Oregon Health & Science University. She has had a long-standing interest in both the clinical and policy aspects of antimicrobial resistance, infection prevention, and infections in older adults. Dr. Malani has published more than 150 peer-reviewed articles and editorials and has edited 5 books. She continues to dabble in journalism, and her recent work has appeared in a variety of publications, including The New York Times, NPR, the Philadelphia Inquirer, and Michigan Rivals. She serves as the Vice Chair of the public health committee of the Infectious Diseases Society of America.

Eleftherios Mylonakis, M.D., Ph.D., is the Charles C.J. Carpenter Professor of Infectious Disease at Brown University. He is also the Chief of Infectious Diseases at Rhode Island Hospital and the Miriam Hospital and the Director of the COBRE Center for Antimicrobial Resistance and Therapeutic Discovery. He is the Assistant Dean for outpatient investigations and the Director of the Center for Outpatient and Longitudinal Medical Research at the Alpert Medical School of Brown University and a Professor of molecular microbiology and immunology. He was previously the Attending Physician of infectious disease at Massachusetts General Hospital and served as an Associate Professor at Harvard Medical School. Dr. Mylonakis studies host and microbial factors of infection and the discovery of antimicrobial agents. His research encompasses both clinical and laboratory studies and the use of mammalian and invertebrate model hosts systems to identify novel antimicrobial compounds and the elucidation of evolutionarily conserved aspects of microbial virulence and the

host response. He has secured 8 patents, edited 5 books, and published more than 400 articles in the peer-reviewed literature. He is currently named as a Principal Investigator on a study of novel antimicrobials for KODA Therapeutics.

Iruka N. Okeke, Ph.D., is a Professor of pharmaceutical microbiology at the University of Ibadan, Nigeria, and a Fellow of the Nigerian and African Academies of Science. Her research group investigates the mechanisms bacteria use to colonize humans, cause disease, and gain drug resistance. She also studies laboratory practice in Africa. Dr. Okeke is a member of Nigeria’s Technical Working Group on Antimicrobial Resistance, and her laboratory currently provides the genomic surveillance service for Nigeria’s antimicrobial resistance surveillance system as part of a collaborative UK National Institute for Health–supported Global Health Research Unit. Dr. Okeke received a B.Pharm., an M.Sc., and a Ph.D. from Obafemi Awolowo University (formerly University of Ife), Nigeria, and postdoctoral training at the University of Maryland, United States, and Uppsala Universitet, Sweden. She has held Fulbright, International Federation for Science, Branco Weiss (Society-in-Science), and Institute for Advanced Studies (Berlin) fellowships as well as academic positions in Nigeria, the United Kingdom, and the United States. Dr. Okeke is author or co-author of several scientific articles and chapters as well as the books Divining Without Seeds: The Case for Strengthening Laboratory Medicine in Africa (Cornell University Press) and Genetics: Genes, Genomes, and Evolution (Oxford University Press). She is the Editor-in-Chief of the African Journal of Laboratory Medicine. Dr. Okeke currently serves as a volunteer drug resistance consultant to the Nigeria Centre for Disease Control, the World Health Organization, and other organizations.

Emmanuel Okello, M.Sc., Ph.D., is an Assistant Cooperative Extension Specialist in antimicrobial stewardship at the University of California (UC), Davis. The goal of his extension program is to develop antimicrobial stewardship guidelines and best management practices that reduce the spread of antimicrobial resistance while maintaining the health and welfare of the herds and flocks. His research work is focused on understanding the dynamics and risks for antimicrobial resistance in livestock and the development of health management strategies for reduced antimicrobial resistance and improved health and welfare of herds and flocks. Other areas of interest include the use of alternatives to antibiotics to control infectious diseases in livestock and the development and evaluation of vaccines and rapid diagnostics tests. Prior to joining the UC Davis faculty in 2018, Dr. Okello was a postdoctoral scholar at the UC Davis Veterinary Medicine Teaching and Research Center in Tulare, Cali-

fornia. His postdoctoral research included surveillance for antimicrobial resistance on California dairies and developing decision tools to guide antimicrobial drug use for dairy cows. Dr. Okello earned his Bachelor of Veterinary Medicine from Makerere University in Uganda, Master of Molecular Biology from Katholieke Universiteit Leuven, and a doctorate in bio-engineering sciences from Vrije Universiteit Brussel in Belgium.

Aylin Sertkaya, Ph.D., is a Vice President and a Senior Economist at Eastern Research Group, Inc. (ERG) with more than 20 years of experience in health economics, econometrics, health policy analysis, and program evaluation. Throughout her career at ERG, she has formed and led teams of economists, scientists, and nationally recognized subject-matter experts to support dozens of high-profile regulatory initiatives, working closely with federal agency economists and policy makers. Her applied research has been published in peer-reviewed journals, such as the American Journal of Infection Control, Applied Health Economics and Health Policy, Clinical Trials, and Human and Ecological Risk Assessment. Dr. Sertkaya has led dozens of economic/policy analysis studies related to antibacterial products, diabetes intervention, unit dose medication barcoding, adoption of MedDRA for postmarketing periodic safety report submissions to the Food and Drug Administration (FDA), drug compounding, among others under contract to FDA and the Department of Health and Human Services’ Office of the Assistant Secretary for Planning and Evaluation. Her research on antibacterial products includes (1) the development of an analytical framework for evaluating the impact of different types of incentives on antibacterial product development, including drugs, vaccines, and rapid point-of-care diagnostics (see published reports Analytical Framework for Examining the Value of Antibacterial Products and Economic Incentives for the Development of Rapid Point-of-Care (POC) Diagnostic Devices for C. difficile, Carbapenem-resistant Enterobacteriaceae (CRE), and Neisseria Gonorrhoeae), and (2) the evaluation of the market performance of antibacterial drugs against their clinical value; examination of potential market failures that underlie lack of appropriate current or projected antibacterial therapies; and (3) modeling the economic burden of antimicrobial resistance (ongoing project). Dr. Sertkaya holds a Ph.D. in economics and a dual bachelor’s degree in physics and economics.

Michelle Soupir, Ph.D., is a Professor and the Associate Chair for research and extension in the Department of Agricultural and Biosystems Engineering at Iowa State University. Her research program focuses on sustainable water systems with an emphasis on nonpoint source pollution control, watershed management, and water quality monitoring. Her research projects encompass multiple scales to answer basic and applied

research questions regarding the occurrence, fate, and transport of pathogens, pathogen indicators, and nutrients and contaminants of emerging environmental concern, such as antibiotics and antimicrobial resistance (AMR) to surface and groundwater systems. Her work is focused on the impacts of agricultural practices, primarily application of manure, on water quality. Through unique environmental monitoring, she works to design conservation practices to mitigate the impact of agricultural nonpoint source pollution on downstream waters and reduce public exposure to these contaminants. Her recent work on AMR has included evaluation of prairie strips as a mitigation strategy to reduce export to downstream waters and watershed-scale monitoring of AMR indicators.

Andy Stergachis, Ph.D., M.S., B.Pharm., is a Professor of pharmacy and global health and an Adjunct Professor of health metrics sciences, epidemiology, and health systems and population health, the Director of the Global Medicines Program, and the Associate Dean for research, Graduate Studies and New Initiatives, School of Pharmacy, University of Washington (UW). He is also the Interim Director of the UW Biomedical Regulatory Affairs Program. Previously, he served as the Chair of UW’s Department of Pharmacy and Department of Pathobiology, and the Associate Dean of the School of Public Health and the founding Director of the UW Pharmaceutical Outcomes Research and Policy Program, now the CHOICE Institute. He is an author of 175 peer-reviewed publications in areas such as pharmacovigilance, pharmacoepidemiology, and clinical epidemiology. A licensed pharmacist, he served as the Editor-in-Chief of the Journal of the American Pharmacists Association for 6 years until 2019. He was a member of the Drug Safety and Risk Management Advisory Committee, a member of the Food and Drug Administration, and chaired the Expert Panel on the Review of Surveillance and Screening Technologies for the Quality Assurance of Medicines for United States Pharmacopeial Convention through 2020. His current research in the field of antimicrobial resistance (AMR) includes serving as the Co-Investigator for a study to estimate the magnitude and trends in the global burden of AMR. Called the Global Research on Antimicrobial Resistance (GRAM) Project, he collaborates with the UW Institute for Health Metrics and Evaluation and the University of Oxford. He recently worked with the U.S. Agency for International Development–funded Medicines, Technologies, and Pharmaceutical Services Program and Management Services for Health to conduct antimicrobial consumption and antimicrobial use projects in Tanzania. He recently joined Vivli’s AMR Register Scientific Advisory Board. He is a pioneer in the validation and use of large linked databases to evaluate the safety of medicines used in the United States and, separately, in low- and middle-income countries. Dr. Stergachis is an elected member of the

National Academy of Medicine and a Fellow of the American Pharmacists Association and the International Society for Pharmacoepidemiology. He has served on multiple National Academies of Sciences, Engineering, and Medicine committees, including the Committee on Evidence-Based Practices for Public Health Emergency Preparedness and Response; the Committee to Review Long-Term Effects of Antimalarial Drugs; the Committee on Strengthening Regulatory Systems in Developing Countries; and the Committee to Assess the U.S. Drug Safety System.

Mary E. Wilson, M.D., is a Clinical Professor of epidemiology and bio-statistics at the University of California, San Francisco, and an Adjunct Professor of global health and population at the Harvard T.H. Chan School of Public Health, Boston. Her academic interests include antibiotic resistance, the ecology of infections and emergence of microbial threats, travel medicine, tuberculosis, and vaccines. She is a fellow of the Infectious Diseases Society of America, the American College of Physicians, the American Society of Tropical Medicine and Hygiene, and the International Society of Travel Medicine. She has served on the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention (CDC) and the Academic Advisory Committee for the National Institute of Public Health in Mexico, and on five committees for the National Academies of Sciences, Engineering, and Medicine, where she was the Vice Chair of the Forum on Microbial Threats through 2019. She was a member of the Pew National Commission on Industrial Farm Animal Production, whose report, Putting Meat on the Table: Industrial Farm Animal Production in America, was released in 2008. She is the author of A World Guide to Infections: Diseases, Distribution, Diagnosis (Oxford University Press, 1991); the Senior Editor, with Richard Levins and Andrew Spielman, of Disease in Evolution: Global Changes and Emergence of Infectious Diseases (New York Academy of Sciences, 1994); the Editor of New and Emerging Infectious Diseases (Medical Clinics of North America, 2008); the author of Antibiotics: What Everyone Needs to Know (Oxford University Press, 2019); and one of the medical editors for the CDC’s Health Information for International Travel (The Yellow Book). She has served as an advisor to the GeoSentinel Surveillance Network and is a contributing editor for the NEJM Journal Watch Infectious Diseases. She served on the Board of Trustees for icddr,b in Bangladesh for 6 years, is a member of the Advisory Board for the Fogarty International Center at the National Institutes of Health, and is on the Board of Directors for the Center for Disease Dynamics, Economics & Policy.

Qijng Zhang, M.S., Ph.D., is the Clarence Hartley Covault Distinguished Professor and the Associate Dean for research and graduate studies in

the College of Veterinary Medicine at Iowa State University. Dr. Zhang received his Ph.D. in immunobiology from Iowa State University and postdoctoral training in molecular microbiology from the University of Missouri. Dr. Zhang worked as an Assistant Professor at The Ohio State University prior to returning to Iowa State University. For the past 20 years, Dr. Zhang’s research has focused on antimicrobial resistance (AMR) at the interface of human and animal medicine. His research has discovered emerging AMR threats, novel antibiotic resistance mechanisms, and the co-evolution of bacterial virulence, along with AMR in zoonotic and foodborne pathogens. His work has also provided key insights into the fitness, persistence, and transmission of AMR pathogens in the food chain, facilitating mitigation of AMR at the animal–human interface. In addition to AMR research, Dr. Zhang has broad perspectives on AMR surveillance, mitigation, and stewardship. Dr. Zhang is a fellow of American Academy of Microbiology and the American Association for the Advancement of Science. He is also an honorary diplomate of the American College of Veterinary Microbiologists.